Literature DB >> 12821490

Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae.

Satoshi Ameyama1, Yuko Shinmura, Masahiro Takahata.   

Abstract

The gyrA and gyrB genes of Chlamydia pneumoniae TW-183 were cloned, and their proteins were purified by use of a fusion system with a maltose-binding protein. The 50% inhibitory concentrations of garenoxacin, sparfloxacin, moxifloxacin, gatifloxacin, and levofloxacin were 10.1, 47.5, 39.6, 64.2, and 156.9 microg/ml, respectively, and the MICs against C. pneumoniae TW-183 were 0.008, 0.016, 0.063, 0.125, and 0.25 microg/ml, respectively.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12821490      PMCID： PMC161870          DOI： 10.1128/AAC.47.7.2327-2329.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.

Authors:  J C Fung-Tomc; B Minassian; B Kolek; E Huczko; L Aleksunes; T Stickle; T Washo; E Gradelski; L Valera; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

2.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

3.  In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae.

Authors:  P M Roblin; M R Hammerschlag
Journal:  J Antimicrob Chemother       Date:  1999-10       Impact factor: 5.790

Review 4.  DNA topoisomerases.

Authors:  M Gellert
Journal:  Annu Rev Biochem       Date:  1981       Impact factor: 23.643

5.  In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.

Authors:  Sheila Malay; Patricia M Roblin; Tamara Reznik; Andrei Kutlin; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

6.  Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp.

Authors:  M Donati; M Rodrìguez Fermepin; A Olmo; L D'Apote; R Cevenini
Journal:  J Antimicrob Chemother       Date:  1999-06       Impact factor: 5.790

Review 7.  A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.

Authors:  J T Grayston; L A Campbell; C C Kuo; C H Mordhorst; P Saikku; D H Thom; S P Wang
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

Review 8.  Chlamydia pneumoniae (TWAR).

Authors:  C C Kuo; L A Jackson; L A Campbell; J T Grayston
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

9.  Comparative in vitro activity of garenoxacin against Chlamydia spp.

Authors:  M Donati; G M Pollini; M Sparacino; M T Fortugno; E Laghi; R Cevenini
Journal:  J Antimicrob Chemother       Date:  2002-09       Impact factor: 5.790

10.  Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.

Authors:  L Ferrero; B Cameron; B Manse; D Lagneaux; J Crouzet; A Famechon; F Blanche
Journal:  Mol Microbiol       Date:  1994-08       Impact factor: 3.501
View more
  3 in total

1.  Serine-to-asparagine substitution in the GyrA gene leads to quinolone resistance in moxifloxacin-exposed Chlamydia pneumoniae.

Authors:  Jan Rupp; Andreas Gebert; Werner Solbach; Matthias Maass
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  In vitro activities of garenoxacin and levofloxacin against Chlamydia pneumoniae are not affected by presence of Mycoplasma DNA.

Authors:  Raymond P Smith; Aldona L Baltch; William J Ritz; Andrea N Carpenter; Tanya A Halse; Lawrence H Bopp
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

3.  Functional analysis of three topoisomerases that regulate DNA supercoiling levels in Chlamydia.

Authors:  Emilie Orillard; Ming Tan
Journal:  Mol Microbiol       Date:  2015-11-13       Impact factor: 3.501
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.